Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026

Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, April 30, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.

To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com . A replay of the webcast will be available for up to a year.

About Bio-Rad

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, BIO-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety, and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit BIO-rad.com.

Investor Contact:
Ruben Argueta, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

News Provided by Business Wire via QuoteMedia

BIO
The Conversation (0)
Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Releases Second Episode of Investor Video Series

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
Lexaria Updates Progress on Human Study #7

Lexaria Updates Progress on Human Study #7

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema")... Keep Reading...
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
Lexaria Bioscience (NASDAQ:LEXX)

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...

Interactive Chart

Latest Press Releases

Related News